Targacept TC-5619 has not met the primary outcome measure in a Phase II trial in patients with inattentive-predominant attention deficit/hyperactivity disorder (ADHDi).

The primary outcome measure of the placebo-controlled trial was change from baseline on the inattention subscale of the Conners’ Adult ADHD Rating Scale-Investigator-Rated (CAARS-INV), after four weeks of treatment versus placebo.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

TC-5619 exhibited a similar safety and tolerability profile as of placebo but the placebo dose group patients showed consistent improvement compared to TC-5619 dose group patients.

Targacept board chairman Mark Skaletsky said TC-5619 did not meet the goal in the ADHDi study.

"Based on these results, we have made the determination that we will not pursue further development of TC-5619 in ADHD," Skaletsky said.

See Also:

"Under these circumstances, we are taking additional steps to more closely align our resources with our current operational plan and emphasize the efficient use of Targacept’s capital.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We will limit our investment in our nicotinic pipeline to our ongoing or previously announced clinical programs until the search for a new CEO is successfully completed, and we will implement a further reduction in force."

The double blind, parallel group study randomised 175 patients with ADHDi, ages 18 to 65, of which 153 completed the study.

The study design provided for a four-week screening period, after which patients were randomised into one of three cohorts and received either placebo or one of two doses of TC-5619 (5mg or 25mg) once daily for four weeks in a ratio of 2:1:1 (placebo: low dose: high dose).